Ardena’s Expertise Helps New Treatment for Parkinson’s Disease

Ghent, Belgium 30 August 2021: Ardena, a specialist pharmaceutical contract development and manufacturing organisation (CDMO), has applied its considerable expertise in drug substance development to assist IRLAB of Gothenburg, Sweden, in taking mesdopetam, an oral dopamine D3-receptor antagonist, from pre-clinical up to its phase I and II clinical programs.

This success has led to a licensing agreement for phase III and worldwide commercialization of mesdopetam1, a potential treatment for people living with Parkinson’s diseaseand experiencing levodopa-induced dyskinesia. Mesdopetam is also in early development for Parkinson’s Disease Psychosis (PDP), which is a common symptom of PD.

“We are delighted to have supported IRLAB get investigational mesdopetam to the next phase. Having guided the entire process up to both pre-clinical and GMP scale, as well as supporting the IMPD submissions in different countries, we can now look forward to Phase III,” said Agnese Jurkevica, Site Director, Ardena, Riga. “The positive data we have generated through our successful collaboration has been key to getting this investigational compound a step closer to helping people living with the effects of Parkinson’s disease.”

Mesdopetam (IRL790) is a dopamine D3-receptor antagonist being designed to prevent and treat levodopa-induced dyskinesias (LIDs), a severe form of involuntary movements common in sufferers of Parkinson’s disease (PD). Clinical studies have shown that mesdopetam reduces the dyskinesia increasing good daily ‘On-Time’ for patients. It has also shown antipsychotic properties in preclinical studies.

Source link

more recommended stories